News
03-23-2011, 11:51 PM
Results of the one-year Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD®) study, published today by the New England Journal of Medicine (NEJM), demonstrate that Spiriva® (tiotropium), is superior to salmeterol, in reducing the risk of exacerbations in Chronic Obstructive Pulmonary Disease (COPD).
More... (http://www.news-medical.net/news/20110324/Study-demonstrates-superiority-of-Spiriva-over-salmeterol-in-reducing-risk-of-exacerbations-in-COPD.aspx)
More... (http://www.news-medical.net/news/20110324/Study-demonstrates-superiority-of-Spiriva-over-salmeterol-in-reducing-risk-of-exacerbations-in-COPD.aspx)